Drug Profile
MEDI 570
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Developer MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; Inducible T-cell co-stimulator protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 31 Dec 2012 Discontinued - Phase-I for Systemic lupus erythematosus in Canada (SC)
- 31 Dec 2012 Discontinued - Phase-I for Systemic lupus erythematosus in Mexico (SC)
- 31 Dec 2012 Discontinued - Phase-I for Systemic lupus erythematosus in USA (SC)